RESEARCH PAPER

Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up-regulation of 15-deoxy $\Delta^{12,14}$ Prostaglandin J_2 production

Jillian Davidson, Warren Higgs and Dino Rotondo

Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK

Correspondence

Dino Rotondo, Strathclyde
Institute of Pharmacy &
Biomedical Sciences, University
of Strathclyde, 161 Cathedral
Street, Glasgow G4 0RE, UK.
E-mail: d.rotondo@strath.ac.uk

Keywords

eicosapentaenoic acid; fever;
15d-PG J_2 ; PGE $_2$; interleukin-1 β

Received

29 May 2012

Revised

5 March 2013

Accepted

22 March 2013

BACKGROUND AND PURPOSE

Eicosapentaenoic acid (EPA) has been shown to suppress immune cell responses, such as cytokine production and downstream PG production *in vitro*. Studies *in vivo*, however, have used EPA as a minor constituent of fish oil with variable results. We investigated the effects of EPA on systemic inflammatory responses as pure EPA has not been evaluated on immune/inflammatory responses *in vivo*.

EXPERIMENTAL APPROACH

Rabbits were administered polyinosinic: polycytidylic acid (poly I:C) i.v. before and after oral treatment with EPA for 42 days (given daily). The responses to IL-1 β and TNF- α were also studied. Immediately following administration of poly I:C, body temperature was continuously monitored and blood samples were taken. Plasma levels of IL-1 β , PGE $_2$ (PGE $_2$), and 15-deoxy- $\Delta^{12,14}$ -PG J_2 (15d-PG J_2) were measured by enzyme immunoassay.

KEY RESULTS

Following EPA treatment, the fever response to poly I:C was markedly suppressed compared with pretreatment responses. This was accompanied by a parallel reduction in the poly I:C-stimulated elevation in plasma levels of IL-1 β and PGE $_2$. Paradoxically, the levels of 15d-PG J_2 were higher following EPA treatment. EPA treatment did not significantly alter the fever response or plasma levels of PGE $_2$ in response to either IL-1 β or TNF- α .

CONCLUSION AND IMPLICATIONS

Oral treatment with EPA can suppress immune/inflammatory responses *in vivo* via a suppression of upstream cytokine production resulting in a decreased fever response and indirectly reducing circulating levels of PGE $_2$. EPA also enhances the production of the cytoprotective prostanoid 15d-PG J_2 indicating the therapeutic benefit of EPA.

Abbreviations

EPA, eicosapentaenoic acid; NSAIDs, non-steroidal anti-inflammatory drugs; poly I:C, polyinosinic:polycytidylic acid

Introduction

The C20:5 fatty acid, eicosapentaenoic acid (EPA), has been shown to have direct modulatory functions in cells and

tissues. EPA can directly result in vasorelaxation of either noradrenaline or high potassium pre-contracted aortae in an endothelium-independent manner (Engler *et al.*, 2000). This vasoactive action appears to be mediated via the activation of

K⁺/ATP channels. It has also been shown that EPA can also have an opposite effect on other ion channels. EPA can directly inhibit Na⁺ channels in cell lines (Nakajima *et al.*, 2009). A direct modulatory effect of EPA *in vitro* has also been demonstrated in immune cells. Human alveolar macrophages incubated with EPA released much lower levels of the obligatory pro-inflammatory cytokines IL-1 β and TNF- α in response to LPS stimulation (Mickleborough *et al.*, 2009). This would indicate that EPA should have an anti-inflammatory action *in vivo*; however, although the direct actions of pure EPA have been clearly demonstrated *in vitro*, very few studies have been able to confirm this *in vivo*. There are many studies that have implied the modulatory actions of EPA but have used a heterogeneous mixture of 'fish oils', which have a very wide variety of different fatty acids with EPA comprising as little as 4% from some sources and a maximum of 14% in others (Ackman *et al.*, 1988). The present study used pure EPA.

Studies using heterogeneous fish oils have shown that markers of inflammation are down-regulated, indicating that fish oils do contain components that are anti-inflammatory (De Caterina *et al.*, 2000). The mechanism by which EPA-containing agents suppress inflammation remains unclear. Potential interference could occur at several points in the sequence of steps involved in the development of systemic inflammatory responses (Romanovsky *et al.*, 2005). These include production of cytokines (upstream mediators), suppression of prostanoids (downstream mediators of symptoms) or the synthesis of novel anti-inflammatory eicosanoids. Recent studies indicate that 15-deoxy- $\Delta^{12,14}$ -PG J₂ (15d-PGJ₂), a cyclopentenone PG and dehydration product of PGD₂ (a major product of immune/inflammatory cells, including monocytes, macrophages and dendritic cells) possesses anti-inflammatory activity (Herlong and Scott, 2006). Elevated plasma levels of 15d-PGJ₂ appear to play a role in abrogating the inflammatory response that contributes to cell death in neurological disorders following acute ischaemic stroke (Blanco *et al.*, 2005) indicating that it is an important cytoprotective mediator. However, the main critical downstream mediator of systemic inflammatory responses (the fever response) is PGE₂ and is the primary therapeutic target for non-steroidal anti-inflammatory drugs (NSAIDs) (Mackowiak, 2000).

We have previously characterized in depth the responses to the TLR3 ligand, polyinosinic: polycytidylic acid (poly I:C), which induces a systemic inflammatory response (Abul *et al.*, 1987; Rotondo *et al.*, 1987; 1988) manifest as a fever when administered intravenously to rabbits. The changes in body temperature (fever) are a direct result of the sequential production of cytokines including IL-1 β (see Fortier *et al.*, 2004) and TNF- α as a first wave and the consequent production of PGs, particularly PGE₂. The prostanoids act at a variety of specific receptors, both in the peripheral circulation (to regulate cytokine production) and in the CNS at the hypothalamic thermoregulatory centre (see Alexander *et al.*, 2011 for prostanoid receptor classification). The levels of PGE₂ increase in both the peripheral circulation and in the cerebrospinal fluid (Rotondo *et al.*, 1988; Davidson *et al.*, 2001) in response to Poly I:C (and also to LPS in a qualitatively identical manner). The aim of the present study was, therefore, to determine whether pure EPA could modulate a systemic inflammatory challenge and have any effect on

blood levels of either IL-1 β , PGE₂ or 15d-PGJ₂. Since pro-inflammatory cytokines are induced in response to challenge with poly I:C, modulation of the response to IL-1 β and TNF- α following EPA supplementation was also determined as this would be a strong indicator of what level in the sequence of events may be modulated preferentially by EPA. We report that EPA suppresses the systemic response in rabbits to challenge with poly I:C. This occurs simultaneously with a decrease in plasma levels of IL-1 β and PGE₂ and an increase in plasma levels of 15d-PGJ₂. Our results suggest that EPA attenuates systemic inflammatory responses by suppressing pro-inflammatory cytokine release and promoting the production of 'anti-inflammatory/cytoprotective' PGs.

Materials and methods

Measurement of body temperature

Dutch rabbits (1.9–2.6 kg) were used throughout the study, and while not being used for experiments, rabbits were individually caged and maintained at 21–23°C. Lights were on 10–12 h per day and food and water were available *ad lib*. All procedures were carried out in compliance with the ethical guidelines laid down by the Home Office. In order to minimize any error in body temperature measurements due to restraint stress, rabbits were accustomed to conventional stocks over a period of 5 days before being used in any experiments. All experiments were performed at an ambient temperature of 22–24°C. Body temperature was measured using Yellow Springs rectal thermistor probes (401 series). Probes were connected to a Biopac Systems model MP100 data acquisition unit and Acqknowledge software (supplied by D. Med Systems Ltd, Oxford, UK) controlled by an Apple Macintosh computer.

Administration of EPA

Rabbits were given 40 mg·kg⁻¹ of purified EPA orally every day for a period of 42 days. Purified EPA, comprised 94% EPA ethyl ester, 4.6% free fatty acids (EPA) and 0.17% α -tocopherol (National Institutes of Health, Bethesda, MD, USA – Biomaterials Test Program).

Immunostimulation challenge of animals with Poly I:C, TNF- α and IL-1 β

Immediately prior to EPA supplementation (control/pre-treatment) and at various intervals thereafter, animals were challenged with different immunomodulatory stimuli (see EPA treatment overview figure). A group of animals were administered 2.5 μ g·kg⁻¹ of polyinosinic: polycytidylic acid (poly I:C). On each occasion, the animal's body temperature was monitored continuously for 5 h, and blood samples were taken at various intervals (as shown in the results section). In a separate series of experiments groups of rabbits were also challenged with either (i) rabbit recombinant rabbit IL-1 β (2000 U·kg⁻¹ – see Davidson *et al.*, 1990) or (ii) TNF- α (10 μ g·kg⁻¹ – see Davidson *et al.*, 1992) and body temperature measured for 3 or 4 h respectively (the duration of fever responses to each stimuli). Blood samples were taken immediately before administration of either of the stimuli and during the peak increase in fever response. Poly I:C (Sigma,

Dorset, UK), TNF- α and IL-1 β (Glaxo, Geneva, Switzerland) were dissolved in sterile saline and administered i.v. via the marginal ear vein.

Blood sampling

Blood samples were taken immediately prior to injection of any of the stimuli and at 90 and 210 min after poly I:C or after 45 min for IL-1 β and 60 min for TNF- α (peak fever responses for each of these cytokines). Plasma levels of PGE₂, 15d-PGJ₂ and rabbit IL-1 β were determined using commercially available assay kits. Briefly, samples were taken from the marginal ear vein at various times as described in the results section by making a small longitudinal incision with a sterile scalpel blade. The first few drops of blood were discarded and 1 mL collected into either ice-cold Eppendorf tubes containing 100 μ L of 4.5 mM-EDTA and 50 μ L of 0.5 mg·mL⁻¹ ketoprofen (PG analysis) or empty Eppendorf tubes (IL-1 β analysis). Immediately after collection, blood samples were centrifuged at 13 000 g for 1 min and plasma either processed further as described below for PG measurement or stored at -80°C for subsequent measurement of rabbit IL-1 β .

Processing of samples for PG measurements

Aliquots of plasma (0.5 mL) were transferred to Eppendorf tubes containing 50 μ L of 1 M HCl to give a final pH of 3.5–4.0. The acidified plasma was then passed through a Sep-Pak C₁₈ column (Waters Associates, Milford, MA, USA), previously prepared by successive washing with 2 mL of methanol and 5 mL of distilled water. The column was then washed with 5 mL of distilled water and the eluate discarded. A further 2 mL of methanol was then passed through the column, the first 0.5 mL of eluate was discarded, and the remainder collected into Eppendorf tubes.

Samples were stored at -80°C for subsequent analysis of PGE₂ and 15d-PGJ₂. Recovery of PGs from samples was determined by the addition of different known concentrations of [³H] PGE₂ or authentic 15d-PGJ₂ to acidified plasma, which were then passed through Sep-Pak C₁₈ columns as described above and radioactivity in the eluate determined by liquid scintillation counting or amount estimated by ELISA respectively. The efficiency of the Sep-Pak C₁₈ columns in extracting PGE₂ was estimated to be greater than 94% and recovery of 15d-PGJ₂ from samples was routinely found to be greater than 86%.

Measurement of PGE₂ and 15d-PGJ₂

For measurement of PG in each sample, aliquots of 100 μ L of methanol were placed into Eppendorf tubes and evaporated to dryness under nitrogen. Assay buffer (100 μ L), was then added to each tube and PGE₂ and 15d-PGJ₂ determined using the corresponding commercially available assay kit as directed by the manufacturer. PGE₂ was estimated using R & D Systems Parameter PGE₂ EIA kit. The inter-assay and intra-assay coefficient of variance (CV) were 8.4 and 3.8% respectively (100 pg·mL⁻¹). 15d-PGJ₂ was estimated using Assay Designs Correlate-EIA 15d-PGJ₂ EIA kit (Ann Arbor, MI, USA). The inter-assay and intra-assay coefficient of variance CV were 6.6 and 5.4% respectively (250 pg·mL⁻¹). To obviate potential measurement artefacts, this assay was evaluated for its ability to measure the target PG using authentic pure

15d-PGJ₂ purchased from an alternative source (Cayman Chemicals, SPI-Bio, Montigny-le-Bretonneux, France) and found to have 93% reactivity compared with the standard supplied in the kit. The ability of the kit antibodies to bind to EPA and so generate false results was also evaluated. Absorbance values of samples of plasma, spiked with EPA then extracted using Sep-Pak C₁₈ columns as described earlier were below the limit of detection indicating the assay did not erroneously measure EPA.

Measurement of IL-1 β

IL-1 β levels in plasma samples were measured using an ELISA Kit (Endogen, supplied by Bradsure, Loughborough, UK). Briefly, aliquots of plasma (100 μ L) or standard authentic IL-1 β were placed into the wells of 96-well plates pre-coated with primary anti-rabbit IL-1 β antibody. Plates were incubated for 2 h at 22°C after which wells were washed with PBS buffer and HRP-labelled secondary anti-rabbit IL-1 β antibody (100 μ L) was added and incubated for a further 2 h at 22°C. Plates were finally washed three times with PBS and tetramethylbenzidine was added (100 μ L) for 30 min at 22°C after which 0.1N H₂SO₄ was added (50 μ L) and the absorbance (at 450 nm) of each well measured in a plate reader.

Presentation of data and statistics

Body temperature measurements are shown either as the change in body temperature from basal (ΔT i.e. $\Delta^\circ\text{C}$), or as a thermal response index (TRI). TRI₅, TRI₄ and TRI₃ values represent the magnitude of changes (area under the curves - $\Delta^\circ\text{C}\cdot\text{hr}$) in body temperature over 5, 4 and 3 h respectively (this matched the duration of responsiveness of animals to the different stimuli, Poly I:C, TNF- α and IL-1 β respectively). A TRI value of 1 represents an increase of 1°C for 1 h, thus a TRI₅ is the magnitude of the response (area under the curve) over 5 h. Plasma levels of PGE₂, 15d-PGJ₂ and rabbit IL-1 β are presented as pg·mL⁻¹ of plasma. All results are expressed as the mean of *n* experiments $\pm$ the SEM. Data were analysed using a paired Student's *t*-test, each animal acting as its own control.

Results

Effect of EPA on poly I:C-induced fever

Poly I:C (2.5 $\mu\text{g}\cdot\text{kg}^{-1}$ i.v.) produced a biphasic increase in body temperature, the first peak occurring 90 min and the second peak 210 min after injection. EPA supplementation attenuated both peaks of the fever response. ΔT -values following EPA administration for 28 and 42 days in comparison with the pretreatment levels (control) are shown in Figure 1. The magnitude of suppression of the response by EPA increased with increasing duration of administration. TRI₅ values were significantly reduced from $3.69 \pm 0.32^\circ\text{C}\cdot\text{h}$ before EPA (pretreatment) to $2.54 \pm 0.34^\circ\text{C}\cdot\text{h}$ ($P < 0.05$) after 28 days and to $1.71 \pm 0.22^\circ\text{C}\cdot\text{h}$ ($P < 0.001$) after 42 days (Figure 2). Suppression by EPA appeared to be maintained after supplementation was discontinued, TRI₅ values of $1.87 \pm 0.21^\circ\text{C}\cdot\text{h}$ obtained on day 63 (21 days following the end of EPA administration) were lower than pretreatment controls ($P < 0.001$). In a separate series of treatments animals were administered poly I:C (2.5 $\mu\text{g}\cdot\text{kg}^{-1}$ i.v.) then sham-treated (no EPA was administered)

Figure 1

Effect of EPA on the fever response to poly I:C. Rabbits were challenged with poly I:C ($2.5 \mu\text{g}\cdot\text{kg}^{-1}$ i.v.) at time 0 and body temperature monitored for 5 h. Body temperature is presented as the change from basal (ΔT), immediately prior to injection of poly I:C. Values shown are for pre-EPA (pretreatment -day 0, open circles), and following daily oral administration of EPA ($100 \text{ mg}\cdot\text{kg}^{-1}$) for 28 days (open triangles) and 42 days (closed circles). All values represent mean $\pm$ SEM for $n = 8$ animals.

for 42 days prior to administration of another dose of poly I:C ($2.5 \mu\text{g}\cdot\text{kg}^{-1}$ i.v.) on day 42. The fever responses prior to treatment compared with the response on day 42 were not significantly different with a TRI_5 value of $3.61 \pm 0.29^\circ\text{C}\cdot\text{h}$ on day 0 and $3.78 \pm 0.36^\circ\text{C}\cdot\text{h}$ on day 42 ($n = 5$) confirming that in EPA-treated animals, the inhibitory action is due specifically to administration of the EPA.

Effect of EPA on poly I:C-induced changes in plasma PGE₂

Blood samples were therefore taken immediately prior to injection of poly I:C and at 90 and 210 min thereafter for measurement of PGE₂. EPA attenuated the poly I:C-induced increases in plasma levels of PGE₂ (Figure 3). PGE₂ levels were reduced from $190 \pm 31 \text{ pg}\cdot\text{mL}^{-1}$ at 90 min and $200 \pm 37 \text{ pg}\cdot\text{mL}^{-1}$ at 210 min in control pretreatment animals to $105 \pm 10 \text{ pg}\cdot\text{mL}^{-1}$ and $112 \pm 10 \text{ pg}\cdot\text{mL}^{-1}$, respectively, following 42 days of EPA administration (both $P < 0.05$).

Effect of EPA on poly I:C-induced changes in plasma 15d-PGJ₂

Blood samples were also taken immediately prior to injection of Poly I:C and at 90 and 210 min thereafter for measurement of 15d-PGJ₂. Administration of poly I:C induced an increase in circulating levels of 15d-PGJ₂ (Figure 4). The Poly I:C induced an 11.7-fold and a 7.4-fold increase in blood levels of 15d-PGJ₂ at 90 min and 210 min respectively compared to pretreatment. In contrast to its suppressive effect on PGE₂ levels (Figure 3), 42 days of treatment with EPA appeared to enhance both basal and poly I:C-induced increases in blood levels of 15d-PGJ₂ (Figure 4). Blood levels of 15d-PGJ₂ in

Figure 2

Magnitude of the fever response to poly I:C before, during and post-EPA administration. Rabbits were challenged with poly I:C ($2.5 \mu\text{g}\cdot\text{kg}^{-1}$ i.v.), and body temperature measured for 5 h. The magnitude of the fever responses are presented as TRI_5 ($^\circ\text{C}\cdot\text{h}$) values prior to administration of $100 \text{ mg}\cdot\text{kg}^{-1}$ EPA (pretreatment, open bar), following daily oral administration of EPA for up to 42 and 21 days after EPA administration was stopped (patterned bars). All values represent mean $\pm$ SEM, for $n = 8$ animals. ** $P < 0.01$ and * $P < 0.05$ compared with pretreatment (paired t -test).

response to poly I:C were increased from $75 \pm 11 \text{ pg}\cdot\text{mL}^{-1}$, $880 \pm 49 \text{ pg}\cdot\text{mL}^{-1}$ and $557 \pm 43 \text{ pg}\cdot\text{mL}^{-1}$ to $184 \pm 19 \text{ pg}\cdot\text{mL}^{-1}$, $1193 \pm 86 \text{ pg}\cdot\text{mL}^{-1}$ and $958 \pm 85 \text{ pg}\cdot\text{mL}^{-1}$ following 42 days of EPA treatment at 0, 90 and 210 min after poly I:C challenge respectively (Figure 4).

Effect of EPA on poly I:C-induced changes in plasma IL-1 β

Poly I:C stimulates the production of IL-1 β , therefore, the effect of EPA on plasma levels of endogenous rabbit IL-1 β in response to this stimulus were determined (Figure 4). Blood samples were taken from animals both before (pretreatment) and 42 days after EPA supplementation commenced. EPA appeared to reduce basal levels of IL-1 β compared with pre-supplementation levels; however, this difference was not statistically significantly different. Poly I:C increased plasma levels of IL-1 β by approximately 4.7-fold compared with pre-challenge levels, and this increase was significantly suppressed by EPA. Plasma levels of IL-1 β were reduced from $170.1 \pm 19.8 \text{ pg}\cdot\text{mL}^{-1}$ (pretreatment) to $77.7 \pm 12.8 \text{ pg}\cdot\text{mL}^{-1}$ ($P < 0.01$) following administration of EPA.

Effect of EPA on IL-1 β - and TNF- α induced fever

As cytokines are intermediate mediators in systemic inflammatory responses, the effect of EPA administration on the

Figure 3

Effect of EPA on plasma levels of PGE₂ following i.v. administration of poly I:C. Blood samples were taken at 0 min, immediately prior to injection and at 90 min and 210 min after injection of poly I:C (2.5 µg·kg⁻¹ i.v.). Plasma levels of PGE₂ in response to poly I:C before administration of EPA (open bars, pretreatment) and after administration of EPA for 42 days (patterned bars) were determined by ELISA. All values represent mean ± SEM, for *n* = 8 animals. **P* < 0.05 versus the respective pretreatment value (paired *t*-test).

Figure 4

Effect of EPA treatment on plasma levels of IL-1β and 15d-PGJ₂ following i.v. administration of poly I:C. Blood samples were taken at 0 min (immediately prior to injection), 90 and 210 min after injection of poly I:C (2.5 µg·kg⁻¹ i.v.). Plasma levels of IL-1β were measured by ELISA in 0 and 90 min samples. 15d-PGJ₂ levels were measured in 0, 90 and 120 min samples by EIA. This was carried out for animals before administration of EPA (open bars, pretreatment) and after administration of EPA for 42 days (patterned bars). All values represent mean ± SEM, for *n* = 8 animals. §*P* < 0.01 versus 0 min and **P* < 0.05 versus pre-EPA treatment (paired *t*-test).

fever response to the cytokines, IL-1β and TNF-α was also determined. IL-1β (2000 U·kg⁻¹ i.v.) was administered to animals prior to supplementation (pretreatment – day 0) and 42 days after supplementation with EPA. Similarly, TNF-α (10 µg·kg⁻¹ i.v.) was administered to animals prior to supplementation (pretreatment – day 0) and 42 days after treatment with EPA. EPA treatment did not significantly alter the response to either IL-1β or TNF-α. Prior to EPA administration (day 0), the TRI₃ value for i.v. treatment with IL-1β was 0.90 ± 0.10, and following EPA administration (day 42), the TRI₃ value for IL-1β was 0.93 ± 0.09 (*n* = 5). The TRI₄ value for TNF-α given before EPA treatment was 1.48 ± 0.17 and following EPA administration (day 42), the value was 1.36 ± 0.14 (*n* = 4).

Effect of EPA on IL-1β- and TNF-α induced changes in plasma PGE₂ & 15d-PGJ₂ levels

Plasma levels of both PGE₂ and 15d-PGJ₂ were measured during the fever responses to IL-1β and TNF-α as described earlier. Blood samples were taken from animals immediately prior to the injection of either IL-1β or TNF-α (labelled controls – pretreatment values) or at the peak of fever responses for either cytokine, 45 min for IL-1β and 60 min for TNF-α. In animals that were given either IL-1β or TNF-α prior to EPA treatment, the plasma levels of PGE₂ increased by approximately threefold (Figure 5). The ability of IL-1β or TNF-α to increase the plasma levels of PGE₂ were not significantly altered following 42 days of EPA treatment (Figure 5).

The plasma levels of 15d-PGJ₂ in animals given either IL-1β or TNF-α, prior to EPA treatment, also increased compared with basal levels (Figure 5). Following 42 days of EPA treatment, the levels of 15d-PGJ₂ were moderately higher in

Figure 5

Effect of EPA on plasma levels of PGE₂ and 15d-PGJ₂ following i.v. administration of either IL-1β or TNF-α. Rabbits were challenged with either IL-1β (2000 U·kg⁻¹ i.v.) or TNF-α (10 µg·kg⁻¹ i.v.), both before (controls – pretreatment, open bars) and after 42 days (patterned bars) administration of EPA. Blood samples were taken immediately prior to (control) and following injection of either IL-1β (45 min) or TNF-α (60 min). Plasma levels of PGE₂ were determined by ELISA, and 15d-PGJ₂ were determined by EIA. §*P* < 0.01 versus control (pretreatment) and **P* < 0.05 versus pre-EPA treatment (paired *t*-test).

EPA-treated animals. The EPA treatment did not significantly alter the plasma level 15d-PGJ₂ in response to IL-1β (Figure 5), but it did increase the 15d-PGJ₂ levels in response to TNF-α (*P* < 0.05).

Discussion

Effect of EPA on poly I:C-induced fever

This study examined the effect of daily administration of EPA on the fever response and circulating levels of inflammatory mediators, systemic manifestations of inflammation. In this study, the immunomodulatory effects of pure EPA (>98%) as evaluated and was administered orally in the manner of a pharmaceutical preparation. This was distinct from other *in vivo* studies, where the EPA is given as a fish-oil emulsion incorporated into dietary chow. The advantage of this approach over previous work using fish oils is that each animal received a directly quantifiable amount of EPA with little influence on overall caloric intake. Fever was induced by i.v. administration of the TLR3 ligand poly I:C, a synthetic double-stranded polyribonucleotide, used experimentally to model viral activation *in vivo*, which we have previously shown to induce reproducible fevers in rabbits qualitatively identical to those of LPS, but without demonstrating the profound tolerance observed with LPS (Rotondo *et al.*, 1987). EPA supplementation attenuated both peaks of the fever response (Figure 1). The magnitude of suppression increased with increasing duration of supplementation, reaching a maximum at 42 days (Figure 2). Our observations clearly demonstrate that EPA can suppress immune/inflammatory responses *in vivo*. The dose of EPA used in the present study was comparable with that used in many human studies. We administered 40 mg·kg⁻¹·day, approximately equivalent to 2.8 g·day⁻¹ in human studies (70 kg subjects). Some human

studies have used as much as 4 g·day⁻¹ (Woodman *et al.*, 2003). In our own human studies, we had previously used 1 g·day⁻¹ EPA in subjects (Bonner *et al.*, 1997; Davidson *et al.*, 1997). A recent meta-study of EPA trials has shown that generally, the EPA doses used in human studies is between 1 g·day⁻¹ and 4 g·day⁻¹ (Xin *et al.*, 2012a,b). Thus, the present study used an EPA dose intermediate to those commonly used in human studies.

Effect of EPA on Poly I:C-induced blood levels of inflammatory mediators

Poly I:C stimulated increases in plasma levels of both primary and secondary inflammatory mediators, i.e. cytokines and prostanoids. Levels of IL-1, PGE₂ and 15d-PGJ₂ increased following administration of poly I:C (Figures 3,4). This is in agreement with other studies which have shown that poly I:C stimulate IL-1 production (Matsukura *et al.*, 2006; Mignot *et al.*, 2012). Indeed, the fever response to poly I:C is dependent on IL-1 and has been shown to increase circulating levels of IL-1β in rats (Fortier *et al.*, 2004).

EPA attenuated the poly I:C-induced increases in plasma levels of PGE₂ and this occurred simultaneously with changes in body temperature (Figures 1,3). Since PGs of the E series, particularly PGE₂, are thought to be the final mediators of fever (Milton and Wendlandt, 1971; Ivanov and Romanovsky, 2004), this suggests that the antipyretic and anti-inflammatory actions of EPA, result in part from a reduction in the synthesis and/or release of PGE₂. EPA can reduce plasma levels of PGE₂ by a number of potential mechanisms that have been extensively proposed previously. EPA competitively inhibits the incorporation of AA into membrane phospholipids, therefore reducing the amount of substrate for synthesis of two-series prostanoids such as PGE₂ and so on, effectively reducing their synthesis (Rubin and Laposata, 1992). EPA could also competitively reduce the amount two-

series eicosanoids synthesized by COX enzymes (Lands, 1992). Both COX-1 and COX-2 can oxygenate a range of $n-3$ and $n-6$, 18–22 carbon fatty acids, optimal catalytic efficiency for both isoforms occurs with AA. The difference in structure between EPA and AA, an additional double bond at C17/C18, is responsible for the 'strained' conformation with which EPA binds to the cyclo-oxygenase active site in the COX enzyme, which slows its enzymatic conversion rate and effectively causes EPA to act as an inhibitor (Malkowski *et al.*, 2001). EPA itself is also a substrate for COX and has been shown to be converted to three-series prostanoids (e.g. PGE₃ or PGD₃). This has been quoted as the most likely explanation, whereby EPA can alter end function. Ingestion of fish oil has been shown to reduce concentrations of two-series PGs and to increase three-series prostaglandins *in vivo* (Fischer *et al.*, 1988; Knapp, 1990), which is cited as evidence that switching to three-series prostanoids is responsible for a change in function. This would seem the least plausible explanation, as it would assume a difference in potency between two- and three-series prostanoids, especially E-series PGs. With respect to immune cell responses, this is definitively not the case. It has been demonstrated that PGs E₁, E₂ and E₃ exert equipotent actions on mononuclear cells by suppressing inflammatory cytokine production (Haynes *et al.*, 1992; Dooper *et al.*, 2002). This would clearly indicate that diverting PG production from PGE₂ to PGE₃ would not alter the magnitude of a final response, that is a fever in this case. This does not appear to happen in the present study, rather a decrease in all E series PGs following EPA treatment is the most likely explanation. This view is strengthened by our assay measurement methodology, as the anti-PGE₂ antibody used in this study has an 81.5% cross-reactivity with PGE₃, that is it cannot discriminate E₂ from the E₃. It is without doubt that PGE₃ would have been produced in the present study; however, it was not possible to directly quantitate this. To date, it has been difficult to measure PGE₃ specifically as antibodies that selectively bind to PGE₃ have been difficult to produce. Although physical methods can easily discriminate PGE₂ from PGE₃ (see our previous study, Rotondo *et al.*, 1994), unfortunately, these methods are not sufficiently sensitive to measure the relatively low levels circulating *in vivo*. A similar study (conducted over 8 weeks) showed that the relative levels of PGE₃ compared with PGE₂ were very low following EPA treatment *in vivo* (albeit given as heterogenous fish oils) with a resultant ratio of circa 600:1 PGE₂ to PGE₃, which was elicited from monocytes *ex vivo* (Kearns *et al.*, 1999). Despite the relative ratios, our data clearly show an overall reduction in the PGE measured, which would include PGE₃, and are very likely secondary to a reduction in the levels of cytokines upstream.

Effect of EPA on poly I:C-induced 15d-PGJ₂

Circulating blood levels of 15d-PGJ₂ increased during the fever response to poly I:C (Figure 4). This observation is similar to those of other groups who have detected increased levels of 15d-PGJ₂ in the cerebrospinal fluid of rats 1 day and 2 days after intraperitoneal injection of high doses of the TLR4 ligand, LPS (Mouihate *et al.*, 2004). Enhanced biosynthesis of 15d-PGJ₂ following immune challenge may contribute to the self-limiting nature of inflammatory responses in general and specifically to poly I:C. Many clinical and experimental studies have shown that increases in body temperature

during fever rarely exceed a set limit, and 15d-PGJ₂ appears to belong to a group of endogenous anti-inflammatory/cytoprotective molecules, of which a number have already been identified (e.g. glucocorticoids, α -melanocyte-stimulating hormone, arginine vasopressin and IL-10). EPA treatment increased basal levels of plasma 15d-PGJ₂ compared with pretreatment levels (Figure 4), but had no effect on basal levels of PGE₂ (Figure 3). This may reflect a selective action of EPA on PGD₂ pathways, for example augmentation of PGD synthase activity. In addition, we found that EPA treatment further enhanced poly I:C-stimulated increases in plasma levels of 15d-PGJ₂ (Figure 4). This suggests that 15d-PGJ₂ may contribute to the anti-inflammatory activity of EPA. Our observations suggest that the anti-inflammatory actions of EPA may result from a combination of reduction in PGE₂ biosynthesis (secondary to a reduction in cytokine production) and possibly an increase in 15d-PGJ₂ synthesis.

There are other possible mechanisms by which EPA could down-regulate IL-1 production. Other novel anti-inflammatory eicosanoids may mediate these actions. These include the lipoxins, resolvins, docosatrienes and neuroprotectins (Serhan, 2005). Resolvin E1 (5S,12R,18R-trihydroxy-EPA; RvE1) is an anti-inflammatory mediator endogenously synthesized from EPA by a novel transcellular mechanism involving the sequential actions of aspirin-acetylated COX-2 and 5-lipoxygenase during the spontaneous resolution phase of acute localized inflammation (Arita *et al.*, 2005; Serhan, 2005) and are potential candidates.

Previous work by our group has demonstrated that both glucocorticoids and the glucocorticoid-derived intermediate, annexin-1, can attenuate poly I:C-induced fever (Milton *et al.*, 1989; Davidson *et al.*, 1991) and that these changes in both fever responses and plasma PGE₂ levels (Rotondo *et al.*, 1988) have similar profiles to those following EPA treatment (Figures 1,3). It is also possible that the actions of EPA are actually mediated via steroids. It was interesting to note that EPA pretreatment appeared to attenuate the second peak of the fever response to Poly I:C greater than the first peak (Figure 1), which is also the case for steroids (Davidson *et al.*, 1991). Unsaturated free fatty acids can increase blood levels of cortisol (Widmaier *et al.*, 1995), whereas saturated fatty acids have no effect. This may be a direct action of unsaturated fatty acids on the adrenal cortex, as it has been shown that fatty acids can induce steroidogenesis directly in adrenocortical cells (Sarel and Widmaier, 1995). It has also been demonstrated that EPA can specifically amplify the release of cortisol levels in humans following activation of serotonin-ergic pathways with fenfluramine (Buydens-Branchey *et al.*, 2011). This demonstrates the capability of EPA to modulate steroid pathways. We have previously shown that a novel steroid, 7 β OH-epiandrosterone, can selectively enhance the production of 15d-PGJ₂ while down-regulating PGE₂ production (Davidson *et al.*, 2008). This is similar to the actions of EPA in the present study where EPA appears to increase levels of 15d-PGJ₂ but suppresses PGE₂ levels stimulated by poly I:C. This strengthens the possibility that EPA suppresses cytokine levels via the up-regulation of steroid production which in turn selectively enhances 15d-PGJ₂ levels. An EPA effect on steroid levels may also be responsible for the longer-lasting actions of EPA following cessation of administration. It is clear that EPA has a prolonged action following the end of

administration irrespective of the mechanism (Figure 2). This is well acknowledged in *n*-3 research, which makes crossover studies difficult and ambiguous. The 'washout' of EPA and indeed other long-chain fatty acids used *in vivo* is delayed. The study of Metherel *et al.* (2009) showed that levels of EPA in various blood compartments, including cells, were still significantly above the pretreatment levels 8 weeks after cessation of supplementation. The study used a dose of EPA comparable with the dose used in the present study (3.2 g·day⁻¹/subject), but EPA was only administered for 28 days (Metherel *et al.*, 2009). In an earlier study with a very short 7-day administration of EPA, it was established that the half-life of EPA (in cell phospholipids) following cessation was 2.31 days (Zuijgeest-van Leeuwen *et al.*, 1999). This would equate to circa 33% of the administration period.

Effect of EPA on PPARs

EPA may also act as an anti-inflammatory agent by binding to peroxisome proliferator-activated receptors (PPARs) that exert their regulatory activity at the gene level. EPA can bind to all three subtypes of PPAR but has the greatest affinity for PPAR- γ (Xu *et al.*, 1999). In this study, we observed that EPA enhanced the amount of poly I:C-induced 15d-PGJ₂ present in plasma (Figure 4), and since 15d-PGJ₂ is reported to be an endogenous ligand for PPAR- γ (Forman *et al.*, 1995), it is possible that EPA may also activate PPARs indirectly through enhanced 15d-PGJ₂ production/activity. However, there is increasing evidence that the activation of PPAR- γ by the levels of 15d-PGJ₂ normally found following activation is highly unlikely (see Davidson *et al.*, 2012 for discussion).

Effect of EPA on poly I:C-induced increases in IL-1 β

It is not known whether poly I:C itself can directly stimulate the production of PGs; however, it does induce the synthesis and release of endogenous pro-inflammatory intermediates, such as IL-1, TNF α and interferon, which are pro-inflammatory and induce fever in the rabbit. In this study, we demonstrated that poly I:C increased plasma levels of endogenous IL-1 β compared with pre-challenge levels, and this increase was suppressed by EPA (Figure 4), implying that EPA can attenuate the inflammatory response by suppressing pro-inflammatory cytokine production. Various *in vitro* studies in cultured cells have shown that EPA can decrease IL-1 β and TNF- α mRNA expression by inhibiting activation of the transcription factor, nuclear factor-kappaB (NF κ B) (Novak *et al.*, 2003; Zhao *et al.*, 2004; Li *et al.*, 2005), and NF- κ B plays a pivotal role in signalling pathways leading to the production of pro-inflammatory cytokines.

Effect of EPA on IL-1-induced systemic inflammatory responses

In this study, we found that purified EPA did not attenuate IL-1 β -induced fever. Previous work by other groups have reported that supplementation with fish oils reduces fever in response to IL-1 (Pomposelli *et al.*, 1989; Cooper and Rothwell, 1993). Discrepancies between the data presented here and those of the above authors may be a result of using heterogenous preparations (fish oil), different animal models, different fever-inducing agents or alternative sources of IL-1

and routes of administration. In this study, we have attempted to simulate a 'naturally' occurring fever response by using rabbit IL-1 β , and in order to gain a clearer understanding of the effect of an individual fatty acid and rather than an undefined mixture, we have administered a defined dose of pure EPA. This definitively indicates that EPA specifically attenuates the production of IL-1 (Figure 4) and not the actions of exogenously administered IL-1 (Figure 5), which bypasses the induction step in response to Poly I:C. Similarly, the actions of TNF- α were also affected by EPA treatment (Figure 5).

The data presented here clearly illustrate that EPA can down-regulate systemic inflammatory responses to the TLR3 ligand, poly I:C, specifically suppressing the endogenous production of IL-1 β with the consequential reduction of PGE₂ levels. This is because of the sequential production of IL-1 β followed by prostanoid biosynthesis (see Introduction) and that we have demonstrated that the direct actions of the exogenous upstream mediators (IL-1 β and TNF- α) are unaffected by EPA. We also demonstrate the novel observation that EPA can enhance production of 15d-PGJ₂ following an immune challenge. This also raises the possibility that EPA acts as an effective anti-inflammatory agent *in vivo* by suppressing PGE₂ synthesis secondary to a decrease in proinflammatory IL-1 β and by enhancing production of 15d-PGJ₂. Our observations are consistent with the view that EPA can definitively modulate immune/inflammatory responses *in vivo*.

Acknowledgements

This work was funded in part by the Food Standards Agency and to a lesser extent by Tenovus.

Conflict of interest

There are no conflicts of interests in the execution of this study.

References

- Abul H, Davidson J, Milton AS, Rotondo D (1987). Dexamethasone pre-treatment is antipyretic toward polyinosinic: polycytidylic acid, lipopolysaccharide and interleukin 1/endogenous pyrogen. *Naunyn Schmiedeberg Arch Pharmacol* 335: 305–309.
- Ackman RG, Ratnayake WMN, Olsson B (1988). The basic fatty-acid composition of Atlantic fish oils – potential similarities useful for enrichment of poly-unsaturated fatty-acids by urea complexation. *J Am Oil Chem Soc* 65: 136–138.
- Alexander SP, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edition. *Br J Pharmacol* 164 (Suppl. 1): S1–S324.
- Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S *et al.* (2005). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med* 201: 713–722.

- Blanco M, Moro MA, Davalos A, Leira R, Castellanos M, Serena J *et al.* (2005). Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. *Stroke* 36: 1189–1194.
- Bonner SA, Rotondo D, Davidson J (1997). Eicosapentaenoic acid supplementation modulates the immune responsiveness of human blood. *Prostaglandins Leukot Essent Fatty Acids* 57: 244–244.
- Buydens-Branchey L, Branchey M, Hibbeln JR (2011). Higher n-3 fatty acids are associated with more intense fenfluramine-induced ACTH and cortisol responses among cocaine-abusing men. *Psychiatry Res* 188: 422–427.
- Cooper AL, Rothwell NJ (1993). Inhibition of the thermogenic and pyrogenic responses to interleukin-1 beta in the rat by dietary N-3 fatty acid supplementation. *Prostaglandins Leukot Essent Fatty Acids* 49: 615–626.
- Davidson J, Milton AS, Rotondo D (1990). A study of the pyrogenic actions of interleukin-1 alpha and interleukin-1 beta: interactions with a steroidal and a non-steroidal anti-inflammatory agent. *Br J Pharmacol* 100: 542–546.
- Davidson J, Flower RJ, Milton AS, Peers SH, Rotondo D (1991). Antipyretic actions of human recombinant lipocortin-1. *Br J Pharmacol* 102: 7–9.
- Davidson J, Milton AS, Rotondo D (1992). Alpha-melanocyte-stimulating hormone suppresses fever and increases in plasma levels of prostaglandin E2 in the rabbit. *J Physiol* 451: 491–502.
- Davidson J, Bonner SA, Rotondo D (1997). Eicosapentaenoic acid supplementation attenuates the production of pro-inflammatory cytokines in human blood. *Br J Pharmacol* 122 S: 355–355.
- Davidson J, Abul HT, Milton AS, Rotondo D (2001). Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. *Pflugers Arch* 442: 526–533.
- Davidson J, Wulfert E, Rotondo D (2008). 7beta-hydroxy-epiandrosterone modulation of 15-deoxy-delta12,14-prostaglandin J2, prostaglandin D2 and prostaglandin E2 production from human mononuclear cells. *J Steroid Biochem Mol Biol* 112: 220–227.
- Davidson J, Rotondo D, Rizzo M, Leaver H (2012). Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism. *Br J Pharmacol* 166: 1193–1210.
- De Caterina R, Liao JK, Libby P (2000). Fatty acid modulation of endothelial activation. *Am J Clin Nutr* 71: 213S–223S.
- Dooper MM, Wassink L, M'Rabet L, Graus YM (2002). The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. *Immunology* 107: 152–159.
- Engler MB, Engler MM, Browne A, Sun YP, Sievers R (2000). Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5n-3) in WKY rat aorta. *Br J Pharmacol* 131: 1793–1799.
- Fischer S, von Schacky C, Schweer H (1988). Prostaglandins E3 and F3 alpha are excreted in human urine after ingestion of n – 3 polyunsaturated fatty acids. *Biochim Biophys Acta* 963: 501–508.
- Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. *Cell* 83: 803–812.
- Fortier ME, Kent S, Ashdown H, Poole S, Boksa P, Luheshi GN (2004). The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. *Am J Physiol Regul Integr Comp Physiol* 287: R759–R766.
- Haynes DR, Whitehouse MW, Vernon-Roberts B (1992). The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. *Immunology* 76: 251–257.
- Herlong JL, Scott TR (2006). Positioning prostanoids of the D and J series in the immunopathogenic scheme. *Immunol Lett* 102: 121–131.
- Ivanov AI, Romanovsky AA (2004). Prostaglandin E2 as a mediator of fever: synthesis and catabolism. *Front Biosci* 9: 1977–1993.
- Kearns RJ, Hayek MG, Turek JJ, Meydani M, Burr JR, Greene RJ *et al.* (1999). Effect of age, breed and dietary omega-6 (n-6): omega-3 (n-3) fatty acid ratio on immune function, eicosanoid production, and lipid peroxidation in young and aged dogs. *Vet Immunol Immunopathol* 69: 165–183.
- Knapp HR (1990). Prostaglandins in human semen during fish oil ingestion: evidence for in vivo cyclooxygenase inhibition and appearance of novel trienoic compounds. *Prostaglandins* 39: 407–423.
- Lands WE (1992). Biochemistry and physiology of n-3 fatty acids. *FASEB J* 6: 2530–2536.
- Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC *et al.* (2005). EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. *Kidney Int* 67: 867–874.
- Mackowiak PA (2000). A symposium marking 4 millennia of antipyretic pharmacotherapy. *Clin Infect Dis* 31: S153–S243.
- Malkowski MG, Thuresson ED, Lakkides KM, Rieke CJ, Micieli R, Smith WL *et al.* (2001). Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. *J Biol Chem* 276: 37547–37555.
- Matsukura S, Kokubu F, Kurokawa M, Kawaguchi M, Ieki K, Kuga H *et al.* (2006). Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. *Clin Exp Allergy* 36: 1049–1062.
- Metherell AH, Armstrong JM, Patterson AC, Stark KD (2009). Assessment of blood measures of n-3 polyunsaturated fatty acids with acute fish oil supplementation and washout in men and women. *Prostaglandins Leukot Essent Fatty Acids* 81: 23–29.
- Mickleborough TD, Tecklenburg SL, Montgomery GS, Lindley MR (2009). Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. *Clin Nutr* 28: 71–77.
- Mignot CC, Pirottin D, Farnir F, de Moffarts B, Molitor C, Lekeux P *et al.* (2012). Effect of strenuous exercise and ex vivo TLR3 and TLR4 stimulation on inflammatory gene expression in equine pulmonary leukocytes. *Vet Immunol Immunopathol* 147: 127–135.
- Milton AS, Wendlandt S (1971). Effects on body temperature of prostaglandins of the A, E and F series on injection into the third ventricle of unanaesthetized cats and rabbits. *J Physiol* 218: 325–336.
- Milton AS, Abul HT, Davidson J, Rotondo D (1989). Antipyretic mechanism of action of dexamethasone. In: Lomax P, Schonbaum E (eds). *Thermoregulation: Research and Clinical Applications*. Karger: Basel, pp. 74–77.
- Mouihate A, Boisse L, Pittman QJ (2004). A novel antipyretic action of 15-deoxy-Delta12,14-prostaglandin J2 in the rat brain. *J Neurosci* 24: 1312–1318.

- Nakajima T, Kubota N, Tsutsumi T, Oguri A, Imuta H, Jo T *et al.* (2009). Eicosapentaenoic acid inhibits voltage-gated sodium channels and invasiveness in prostate cancer cells. *Br J Pharmacol* 156: 420–431.
- Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ (2003). NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. *Am J Physiol* 284: L84–L89.
- Pomposelli JJ, Mascioli EA, Bistran BR, Lopes SM, Blackburn GL (1989). Attenuation of the febrile response in guinea pigs by fish oil enriched diets. *J Parenter Enteral Nutr* 13: 136–140.
- Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA *et al.* (2005). Fever and hypothermia in systemic inflammation: recent discoveries and revisions. *Front Biosci* 10: 2193–2216.
- Rotondo D, Abul HT, Milton AS, Davidson J (1987). The pyrogenic actions of the interferon-inducer, polyinosinic:polycytidylic acid are antagonised by ketoprofen. *Eur J Pharmacol* 137: 257–260.
- Rotondo D, Abul HT, Milton AS, Davidson J (1988). Pyrogenic immunomodulators increase the level of prostaglandin E2 in the blood simultaneously with the onset of fever. *Eur J Pharmacol* 154: 145–152.
- Rotondo D, Earl CR, Laing KJ, Kaimakamis D (1994). Inhibition of cytokine-stimulated thymic lymphocyte proliferation by fatty acids: the role of eicosanoids. *Biochim Biophys Acta* 1223: 185–194.
- Rubin D, Laposata M (1992). Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. *J Lipid Res* 33: 1431–1440.
- Sarel I, Widmaier EP (1995). Stimulation of steroidogenesis in cultured rat adrenocortical cells by unsaturated fatty acids. *Am J Physiol* 268: R1484–R1490.
- Serhan CN (2005). Novel omega – 3-derived local mediators in anti-inflammation and resolution. *Pharmacol Ther* 105: 7–21.
- Widmaier EP, Margenthaler J, Sarel I (1995). Regulation of pituitary-adrenocortical activity by free fatty acids in vivo and in vitro. *Prostaglandins Leukot Essent Fatty Acids* 52: 179–183.
- Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF *et al.* (2003). Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. *Atherosclerosis* 166: 85–93.
- Xin W, Wei W, Li X (2012a). Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials. *PLoS ONE* 7: e46028.
- Xin W, Wei W, Li X (2012b). Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord* 12: 77–93.
- Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ *et al.* (1999). Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. *Mol Cell* 3: 397–403.
- Zhao Y, Joshi-Barve S, Barve S, Chen LH (2004). Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. *J Am Coll Nutr* 23: 71–78.
- Zuijdgheest-van Leeuwen SD, Dagnelie PC, Rietveld T, van den Berg JW, Wilson JH (1999). Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions. *Br J Nutr* 82: 481–488.